Skip to main content

Table 1 Comparisons of demographic and clinical data between the groups of different HD access related ESBL-Kp bacteremia

From: Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum beta-lactamase producing klebsiella pneumoniaein patients on maintenance hemodialysis

Source of infection HD catheter Fistula Graft ALL
Case No 42 7 8 57
Male (%) 33 (78.6) 6 (85.7) 6 (75) 45 (78.9)
Age, years 64.8 ± 10.0 61 ± 10.5 65.1 ± 7.8 64.4 ± 9.5
Patients aged >65 years (%) 24 (57.1) 3 (42.9) 5 (62.5) 32 (56.1)
Admission for infectious diseases (%) 23 (54.8) 5 (71.4) 6 (75) 34 (59.6)
Significant underlying diseases (%)     
Diabetes mellitus 15 (35.7) 4 (57.1) 7 (87.5) 26 (45.6)
Liver cirrhosis 5 (11.9) 1 (14.3) 2 (25) 8 (14)
Congestive heart failure 10 (23.8) 3 (42.9) 5 (62.5) 18 (31.6)
Malignancy 4(9.5) 1 (14.3) 1 (12.5) 5 (8.8)
Comorbid conditions (%)     
Poor nutritiona 42 (100) 7 (100) 8 (100) 57 (100)
Prior antibiotic useb 37 (88.1) 6 (85.7) 7 (87.5) 50 (87.7)
Previous severe illnessc 35 (83.3) 6 (85.7) 6 (75) 47 (82.5)
Prolonged (>30 days) hospitalization 33 (78.6) 5 (71.4) 6 (75) 44 (77.2)
Prior use of 3rd-generation cephalosporin 27 (64.3) 5 (71.4) 6 (75) 38 (66.7)
ICU stay at or after the onset of bacteremia 20 (47.6) 4 (57.1) 5 (62.5) 29 (50.9)
Pitt bacteremia score 5.29 ± 1.67 5 ± 1.73 6.38 ± 2.26 5.4 ± 1.78
ABx after onset of bacteremia d     
Effective ABx within 5 days (%) 15 (35.7) 3 (42.9) 3 (37.5) 21 (36.8)
Use flomoxef/IMP /MEP as effective ABx(%) 19(45)/13(31)/ 10(24) 4(57)/3(43)/ none 6 (75)/none/ 2(25) 29(51)/16(28)/ 12(21)
Mortality (%) 27 (64.3) 3 (42.9) 6 (75) 36 (63.2)
  1. a albumin < 3.5 g/dL; b including extended-spectrum cephalosporins, aztreonam, fluoroquinolones, trimethoprim/sulfamethoxazole, or aminoglycosides; c includes shock, intubation and ICU stay; d Abx: antibiotics, IMP: imipenem, MEP: meropenem.